Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report) Director Rostislav Christov Raykov sold 2,431 shares of Fennec Pharmaceuticals stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of C$7.45, for a total value of C$18,115.81.
Rostislav Christov Raykov also recently made the following trade(s):
- On Monday, July 1st, Rostislav Christov Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$6.13, for a total transaction of C$14,902.03.
Fennec Pharmaceuticals Stock Performance
TSE:FRX opened at C$7.14 on Friday. The company has a debt-to-equity ratio of 1,040.68, a current ratio of 8.02 and a quick ratio of 10.17. The firm has a market cap of C$195.35 million, a PE ratio of 79.33 and a beta of 0.26. The firm has a 50 day simple moving average of C$8.19 and a 200-day simple moving average of C$10.64. Fennec Pharmaceuticals Inc. has a 1-year low of C$7.00 and a 1-year high of C$15.43.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Read More
- Five stocks we like better than Fennec Pharmaceuticals
- How is Compound Interest Calculated?
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- Election Stocks: How Elections Affect the Stock Market
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.